Oral lichen planus (OLP) is a chronic mucocutaneous disease with an unknown aetiology, affecting 0.5-2% of the population and with a predilection for females in fourth to fifth decade of life. Most oral lichen planus lesions are asymptomatic but the atrophic and erosive forms of OLP can cause symptoms ranging from spontaneous soreness to severe pain interfering with eating, speech and swallowing. Various drugs have been used for the treatment of OLP including corticosteroids and other immunomodulators. However, no therapy is considered as the single most effective and without side effects in the management of this enigmatic disease. In spite of using long-term systemic corticosteroids, side effects were minimal and clinically uneventful. Further controlled trials with this therapy may provide a definitive mode of treatment for severe OLP cases.